Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
PhoreMost Expands into New Facility at Unity Campus, Cambridge, UK
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced […]
NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics
NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in […]
PhoreMost and POLARISqb Announce a Multi-target Collaboration to Investigate Next-generation Cancer Therapies
PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more